Among new therapeutic modalities, targeted therapies have the best efficacy for NSCLC patients, especially those carrying epidermal growth factor receptor (EGFR) mutations (2, 3), However, targeted therapies inevitably generate drug resistance, posing a challenge for the follow-up of NSCLC patients. This evidence concerns the gene EGFR and non-small cell lung carcinoma.